Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

American Journal of Hematology

Volumn 88, Issue 9, 2013, Pages 765-770

  Bagratuni, Tina ^a   Kastritis, Efstathios ^a   Politou, Marianna ^b   Roussou, Maria ^a   Kostouros, Efthimios ^a   Gavriatopoulou, Maria ^a   Eleutherakis Papaiakovou, Evangelos ^a   Kanelias, Nikolaos ^a   Terpos, Evangelos ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; THROMBOMODULIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ACENOCOUMAROL; AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPIRIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE MYELOMA; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SUBUNITS; PULMONARY EMBOLISM; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 84882695550     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23504     Document Type: Article

References (38)

1. Vallet S, Witzens-Harig M, Jaeger D, Podar K. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother 2012;13:473-494.
2. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
3. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.
4. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
5. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-3276.
6. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy. Ann Oncol 2006;17:1766-1771.
7. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: A randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838-5841.
8. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.
9. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865-4873.
10. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010;28:132-135.
11. Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:437-444.
12. Uaprasert N, Voorhees PM, Mackman N, Key NS. Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis. Eur J Cancer 2010;46(:1790-1799.
13. Elice F, Rodeghiero F, Falanga A, Rickles FR. Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 2009;22:115-128.
14. Corso A, Lorenzi A, Terulla V, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004;83:588-591.
15. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 2008;112:4924-4934.
16. Hunter ZR, Boxer M, Kahl B, et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079. J Clin Oncol (Meeting Abstracts) 2006;24:7523.
17. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-3415.
18. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008;112:3582-3586.
19. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 2011;29:986-993.
20. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933-939; quiz 1093.
21. Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for newly-diagnosed multiple myeloma patients treated with lenalidomide. Blood 2011.
22. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
23. Zangari M, Berno T, Zhan F, et al. Mechanisms of thrombosis in paraproteinemias: The effects of immunomodulatory drugs. Semin Thromb Hemost 2012;38:768-779.
24. Zamagni E, Brioli A, Tacchetti P, et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011;37:209-219.
25. Almasi M, Sevcikova S, Slaby O, et al. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin Lymphoma Myeloma Leuk 2011;11:414-420.
26. Kastritis E, Dimopoulos MA. Thalidomide in the treatment of multiple myeloma. Best Pract Res Clin Haematol 2007;20:681-699.
27. Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008;22:1343-1353.
28. Anderson KC. Lenalidomide and thalidomide: Mechanisms of action-similarities and differences. Semin Hematol 2005;42(:S3-S8.
29. Karin M, Greten FR. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759.
30. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-466.
31. Bendjennat M, Boulaire J, Jascur T, et al. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 2003;114:599-610.
32. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle 2004;3:134-137.
33. Bombeli T, Schwartz BR, Harlan JM. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999;93:3831-3838.
34. Kastritis E, Dimopoulos MA. When a little aspirin may be enough. Blood 2012;119:905-906.
35. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis. Blood 2006;108:403; author reply 4.
36. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proc 2005;80:1568-1574.
37. Zappasodi P, Mangiacavalli S, Terulla V, et al. Thrombomodulin levels are not modified during thalidomide treatment. Eur J Haematol 2006;77:453-454.
38. Robak M, Trelinski J, Chojnowski K. Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol 2012;29:3574-3580.